Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomer Meirson

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
NPJ Precision Oncology|July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 FallacyAlexander D Sherry, Pavlos Msaouel, Zachary R McCaw, et al.
JCO Clinical Cancer Informatics|May 1, 2026
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology TrialsAlexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology TrialsAlexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2024
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial MisinterpretationTimothy A Lin, Zachary R McCaw, Alex Koong, et al.
Journal of the National Cancer Institute|February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trialsEric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
NPJ Precision Oncology|July 24, 2025
Survival-inferred fragility of statistical significance in phase III oncology trialsAlexander D Sherry, Yufei Liu, Pavlos Msaouel, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2023
Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 FallacyAlexander D Sherry, Pavlos Msaouel, Zachary R McCaw, et al.
JCO Clinical Cancer Informatics|May 1, 2026
Interpreting Treatment Effects Using Posterior Probabilities: A Bayesian Reanalysis of 230 Phase III Oncology TrialsAlexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology TrialsAlexander D Sherry, Pavlos Msaouel, Gabrielle S Kupferman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2024
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial MisinterpretationTimothy A Lin, Zachary R McCaw, Alex Koong, et al.
Journal of the National Cancer Institute|February 8, 2024
Association of differential censoring with survival and suboptimal control arms among oncology clinical trialsEric J Hsu, Timothy A Lin, Dor R Dabush, et al.
Pageof 6